Latest Earnings Results: Q2 '26
Estimated EPS
-$0.09
Reported EPS
-$0.09
Surprise
+3.57%
Estimated Rev
$47.31M
Reported Rev
$48.14M
Surprise
+1.76%
• Reported GAAP EPS of -$0.09 down -125.00% YoY • Reported revenue of $48.14M up 5.57% YoY • Cytek Biosciences is updating its revenue outlook for the full year 2026 to be in the range of $207 million to $212 million, raising the midpoint by $1 million total.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | -$0.07 | -- | -- | N/A |
Q2 '26 | -$0.09 | -$0.09 | 3.57% | BEAT |
Q1 '26 | -$0.09 | -$0.15 | -62.16% | MISSED |
Q4 '25 | -$0.02 | -$0.34 | -1600.00% | MISSED |
Q3 '25 | -$0.03 | $0.00 | 114.01% | BEAT |